Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $MBII
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/22/2021 | $2.00 | Buy | Roth Capital |
8/19/2021 | $3.50 → $2.50 | Buy | Aegis Capital |
ROTH MKM's Agribusiness Investment Banking Group Sees Success with the Closing of Three M&A Sellside Transactions
ROTH MKM ("Roth"), www.roth.com, a relationship-driven investment bank focused on serving growth companies and their investors, is pleased to announce that their agribusiness investment banking group has advised on three sellside transactions in the past nine months. The transactions included business models in the areas of cover crops, gene editing, biologicals, bio stimulants, and alternative fertilizers, and demonstrate the group's expertise in designing and executing M&A processes to achieve the best outcomes for its clients in a wide array of agriculture related sectors. ROTH MKM's Agribusiness Investment Banking Group served as the sellside advisor on the following transactions:
Bioceres Crop Solutions Completes Merger With Marrone Bio, Creating a Global Leader in Sustainable Agricultural Solutions
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) ("Bioceres" or the "Company"), a fully integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, announced today the successful completion of its previously announced integration of Marrone Bio Innovations, Inc. (NASDAQ:MBII) ("MBI"). "The completion of this transaction represents an important milestone in our journey, cementing our leadership in the development and commercialization of sustainable agricultural solutions," said Bioceres Chief Executive Officer, Federico Trucco. "MBI brings 15 years of experience in the development of biological solutions, and we are excited to a
Marrone Bio Innovations, Inc. Shareholders Approve Merger Agreement with Bioceres Crop Solutions Corp.
RALEIGH, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI) announced that during a special shareholder meeting held on July 8, 2022, its shareholders approved a proposal to adopt the previously announced Agreement and Plan of Merger (Merger Agreement), dated as of March 16, 2022, by and among Bioceres Crop Solutions Corp. (BIOX), BCS Merger Sub, Inc., and MBI, pursuant to which MBI will be acquired by BIOX. At the special meeting, MBI's stockholders approved the adoption of the Merger Agreement and approved on a non-binding advisory basis certain executive compensation that may be paid or become payable in connection with the merger contemplated by t
Roth Capital initiated coverage on Marrone Bio Innovations with a new price target
Roth Capital initiated coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $2.00
Aegis Capital reiterated coverage on Marrone Bio Innovations with a new price target
Aegis Capital reiterated coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $2.50 from $3.50 previously
Canaccord Genuity resumed coverage on Marrone Bio Innovations with a new price target
Canaccord Genuity resumed coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $3.50
SEC Form 4: Vasavada Amit was granted 129,184 shares and returned 285,892 shares to the company, closing all direct ownership in the company
4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)
SEC Form 4: Johnson Timothy B was granted 102,167 shares and returned 212,374 shares to the company, closing all direct ownership in the company
4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)
SEC Form 4 filed by Ospraie Ag Science Llc
4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)
SEC Form 15-12G filed by Marrone Bio Innovations Inc.
15-12G - Pro Farm Group, Inc. (0001441693) (Filer)
SEC Form EFFECT filed by Marrone Bio Innovations Inc.
EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)
SEC Form EFFECT filed by Marrone Bio Innovations Inc.
EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)
180 Life Sciences Corp. Announces the Appointment of Pamela Marrone, PhD and Frank Knuettel II, MBA to Board of Directors
MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Pamela Marrone, PhD, and Frank Knuettel II, MBA, to its Board of Directors (“Board”) effective upon the earlier of (a) the business day following the filing of the 2020 Form 10-K Annual Report; and (b) June 28, 2021. The Board also changed the effective dates of the appointments of Russell T. Ray, MBA and Teresa DeLuca MD, MBA as members of the Board, as previously announced
Marrone Bio Appoints Sue Cheung New Chief Financial Officer
DAVIS, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, announced today that Suping (Sue) Cheung has been appointed chief financial officer, effective Feb. 18, 2021. She succeeds James Boyd, who previously announced his intention to retire. Cheung, a certified public accountant, brings to Marrone Bio 28 years of experience in international strategic and financial operations, including financial reporting, forecasting and budgeting; mergers and acquisitions; equity and debt financing; internal controls; and inves
Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Results
RALEIGH, N.C., May 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the first quarter ended March 31, 2022. Key results include: Higher sales of row crop products in the first quarter were somewhat offset by lower sales into specialty crop markets, which were affected by adverse weather conditions. Based on the strength of current orders, revenues in the first half are expected to increase in the low- to mid-teens on a percentage basis.Gross profit of $6.2 million and gross margins of 55.9% reflected changes in product mix, higher raw material
Marrone Bio Innovations to Report First Quarter 2022 Results on Wednesday, May 11 at 4:30 p.m. Eastern Time
RALEIGH, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the first quarter ended March 31, 2022, after market close on Wednesday, May 11, 2022. Management will host an investor conference call at 4:30 p.m. ET to discuss Marrone Bio Innovations' first quarter financial results, provide a corporate update, and conclude with a Q&A from participants. To participate, please use the following information: Q1 2022 Conference Call and Webcast Date: Wednesday, May 11, 2022Time: 4:30 p.m
Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2021 Financial Results
RALEIGH, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2021. Key results include: Full year revenues rose 15.5%, with a 40.2% increase in the fourth quarter.Gross profit grew 19.1% and 31.5% for the full year and fourth quarter, respectively, with margins exceeding 59% in both periods.For the full year, net loss was $16.6 million and Adjusted EBITDA1 loss was $8.7 million, improvements of 17.9% and 21.2%, respectively.As announced March 16, 2022, Marrone Bio and Bioceres Crop So
SEC Form SC 13D/A filed by Marrone Bio Innovations Inc. (Amendment)
SC 13D/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)
SEC Form SC 13G/A filed by Marrone Bio Innovations Inc. (Amendment)
SC 13G/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)
SEC Form SC 13G/A filed by Marrone Bio Innovations Inc. (Amendment)
SC 13G/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)